| Rosenbaum, David P |
| Recruiting | 3 | 700 | US | Apixaban, Eliquis, Aspirin | Yale University, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage, Atrial Fibrillation | 04/27 | 04/27 | | |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT05905926: Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C |
|
|
| Enrolling by invitation | 3 | 150 | US | Tenapanor, Ibsrela | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 07/31 | 10/31 | | |
NCT06553547: 4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
|
|
| Recruiting | 2 | 72 | US | Tenapanor, IBSRELA, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 06/26 | 06/26 | | |
| Recruiting | N/A | 168 | Europe, US | Tigertriever 13 | Rapid Medical | Ischemic Stroke, Neovascularization | 01/25 | 01/25 | | |
NCT04129125: The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System |
|
|
| Completed | N/A | 328 | US | Zoom Reperfusion System | Imperative Care, Inc. | Ischemic Stroke, Acute Stroke | 05/24 | 05/24 | | |
| Morrar, Nidal |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT05490680: A New Sildenafil Oral Film in Patients With Erectile Dysfunction |
|
|
| Active, not recruiting | 3 | 488 | US | Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg, Sildenafil Orodispersible Film, Placebo, Placebo-controlled | IBSA Institut Biochimique SA | Erectile Dysfunction | 12/24 | 12/24 | | |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD |
|
|
| Recruiting | 3 | 2934 | Europe, Canada, US, RoW | Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | COPD, COPD Exacerbation | 01/26 | 01/26 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 03/29 | 03/29 | | |
ASPIRE, NCT06504446: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough |
|
|
| Recruiting | 2 | 325 | US | NOC-110, taplucainium, Placebo | Nocion Therapeutics, Iqvia Pty Ltd | Refractory or Unexplained Chronic Cough | 11/25 | 11/25 | | |
| Fuller, Christine |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 400 | US | CIN-102 Dose 1, CIN-102 Dose 2, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 10/24 | 10/24 | | |
| Rochine, Peg |
| Completed | 3 | 200 | US | Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo | Cristcot LLC, Cristcot HCA LLC | Ulcerative Proctitis | 07/24 | 09/24 | | |
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis |
|
|
| Recruiting | 2 | 400 | US | CIN-102 Dose 1, CIN-102 Dose 2, Placebo | CinDome Pharma, Inc. | Diabetic Gastroparesis | 10/24 | 10/24 | | |
